Christopher Chum, DO
Gastroenterology · Brooklyn, NYNPI 1144669532
Payments from drug & device makers
What this record shows
27 manufacturers reported payments, led by Olympus Corporation Of The Americas at 27.8% of the total. Reporting peaked in 2024 at $2,854 and has fallen 50.1% since, to $1,423 in 2025.
Across 171 payments — averaging $34.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Olympus Corporation Of The Americas$2K
- Boston Scientific$956
- AbbVie$596
- Ovesco Endoscopy USA, Inc.$561
- Gilead$386
- Johnson & Johnson$173
- plus $2K from 21 others
What the payments were for
- Travel & lodging$2,68846%
- Food & beverage$3,14454%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Olympus Corporation Of The Americas | 18 | $1,623 |
| Boston Scientific | 20 | $956 |
| AbbVie | 37 | $596 |
| Ovesco Endoscopy USA, Inc. | 1 | $561 |
| Gilead | 11 | $386 |
| Johnson & Johnson | 8 | $173 |
| Cook Medical LLC | 5 | $166 |
| Lilly USA, LLC | 4 | $162 |
| Olympus America Inc. | 8 | $161 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 8 | $150 |
| Pfizer | 7 | $128 |
| Ardelyx, Inc. | 5 | $99 |
| Aimmune Therapeutics, Inc. | 6 | $96 |
| Madrigal Pharmaceuticals | 5 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $78 |
| Amgen | 4 | $67 |
| Sanofi | 3 | $64 |
| Ironwood Pharmaceuticals, Inc | 3 | $58 |
| Phathom Pharmaceuticals, Inc. | 5 | $55 |
| Steris Corporation | 2 | $45 |
| Shionogi Inc | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Novo Nordisk | 1 | $18 |
| Merck | 1 | $16 |
| Bristol Myers Squibb | 1 | $16 |
| Ipsen Biopharmaceuticals, Inc | 1 | $16 |
| Organon | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,832 in reported general payments places this provider in the 70th percentile of 1,682 gastroenterology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 55 | $924 |
| Pantoprazole Sodium | 27 | $322 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Brooklyn
- Sam MoskowitzBrooklyn$332K
- Jianjun LiBrooklyn$211K
- Nison BadalovBrooklyn$200K
- Kevin TinBrooklyn$168K
- Jonathan ErberBrooklyn$164K
- Rabin RahmaniBrooklyn$155K
- Kayane Hanna-HindyBrooklyn$151K
- Kadirawelpillai IswaraBrooklyn$148K
- David Carr LockeNew York$2M
- Arthur KornbluthNew York$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.